Thomas C. Tsai

Oct 25, 2024 | jamanetwork.com | Kevin Lin |Thomas C. Tsai

Introduction Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) semaglutide and liraglutide as antiobesity medications has surged in recent years.1,2 Anecdotally, health systems have closed hospital-based metabolic bariatric surgery programs due to decreased demand, but empirical data on the association of increased prescribing of GLP-1 RAs with use of metabolic bariatric surgery is unavailable, to our knowledge.

Jul 11, 2023 | jamanetwork.com | David C. Cron |Thomas C. Tsai |Rachel E. Patzer |Syed Husain

Key PointsQuestion  Is dialysis facility–level commercial payer mix associated with patient access to kidney transplant? Findings  In this cohort study including 233 003 patients receiving incident dialysis, commercial insurance at the patient-level was associated with increased wait-listing for kidney transplant within 1 year, but there was no significant independent association of facility-level commercial payer mix with wait-listing.